Ozempic, Mounjaro, and What Your Doctor Isn’t Telling You
Dr. Francisco Puentes, board-certified endocrinologist, explains how GLP- 1 medications work, who the right candidates are, and why working with a specialist is the difference between real results and real risk.
By Dr. Francisco Puentes, MD, FACE · Board-Certified Endocrinologist · Endocrine Specialists of Georgia -Atlanta, GA
When Diet and Exercise Are Not Enough
If you have spent years trying to lose weight — changing your diet, exercising consistently, trying supplements — and still cannot maintain results, it may not be a willpower issue. According to the American Diabetes Association (ADA) and the American Association of Clinical Endocrinologists (AACE), obesity is a chronic, complex disease with hormonal, metabolic, and neurological components that often require medical intervention beyond lifestyle changes alone.
Dr. Francisco Puentes, MD, FACE, Board Certified endocrinologist with over 30 years of clinical experience in Atlanta, Georgia, offers comprehensive evaluation and supervised treatment with GLP-1 receptor agonists — including semaglutide (Ozempic®/Wegovy®) and tirzepatide (Mounjaro®/Zepbound®) — as part of a personalized, physician-led weight management plan at Endocrine Specialists of Georgia.
“They are very effective. It is the best we have ever had. People may lose four to eight pounds per month during the initial phase. But you must fully evaluate and study the patient before starting.”— Dr. Francisco Puentes, MD, FACE – Endocrine Specialists of Georgia, Atlanta, GA
What Are GLP-1 Medications and How Do They Work?
GLP-1 receptor agonists (Glucagon-Like Peptide-1) are a class of FDA – approved medications used to treat type 2 diabetes and, in higher doses, for chronic weight management. They act on multiple biological systems simultaneously:
- They reduce appetite at the brain level — decreasing hunger signals in the hypothalamus.
- They slow gastric motility, helping patients feel fuller for longer after each meal.
- They improve insulin sensitivity and glucose tolerance, reducing post-meal blood sugar spikes.
Semaglutide (Ozempic® / Wegovy®)
Semaglutide is FDA-approved for type 2 diabetes management (Ozempic®) and chronic weight management (Wegovy®). According to the STEP clinical trial program published in the NEJM, patients in the semaglutide group achieved an average weight reduction of approximately 12–15% of their body weight over 68 weeks, compared to about 2.4% in the placebo group.
Tirzepatide (Mounjaro® / Zepbound®)
Tirzepatide is a dual GIP/GLP-1 receptor agonist — the first of its class. According to the SURMOUNT-1 trial (NEJM, 2022), participants achieved mean weight reductions of 15% to 22.5% of body weight, depending on dosage, over 72 weeks. Dr. Puentes notes that in clinical practice, individual results vary based on adherence, baseline weight, metabolic profile, and comorbidities.
Who May Qualify for GLP-1 Treatment?
Not every patient is a candidate. Dr. Puentes performs a comprehensive medical evaluation before recommending any treatment. General eligibility is based on FDA labeling and AACE/Obesity Medicine Association guidelines:
| Patient Profile | Eligibility per AACE/FDA Guidelines |
| BMI ≥ 30 (obesity). | ✅ May qualify — requires medical evaluation. |
| BMI 27–29 with weight-related comorbidity. | ✅ May qualify if diabetes, hypertension, or CVD is present. |
| Type 2 diabetes, uncontrolled. | ✅ Dual benefit: glycemic control and weight reduction. |
| Pre-diabetes with overweight. | ✅ May reduce progression risk — requires physician assessment. |
| History of pancreatitis. | ⛔ Contraindicated — not recommended per FDA labeling. |
| Thyroid nodules or personal/family history of medullary thyroid carcinoma. | ⛔ Contraindicated per FDA labeling — requires specialist evaluation. |
| Diagnosed gastroparesis | ⛔ Use with caution or contraindicated — worsens gastric motility |
Who May Qualify for GLP-1 Treatment?
Dr. Puentes emphasizes that medication should always complement — not replace — lifestyle modification. This aligns with the AACE/ACE Comprehensive Clinical Practice Guidelines for Medical Care of Patients with Obesity (2016, updated 2023):
- Establish a regular cardiovascular exercise routine (minimum 150 minutes/week per AHA guidelines).
- Reduce refined carbohydrate intake as directed by your physician or registered dietitian
- Complete baseline lab work: fasting glucose, HbA1c, TSH, kidney function, liver enzymes, lipid panel
- Discuss contraindications and personal/family medical history with your endocrinologist
⚠️ Dr. Puentes’ Clinical Warning — Unregulated Compounded Medications.
Unfortunately, many patients purchase compounded versions of these medications from online pharmacies or med-spas without proper medical evaluation. The FDA has issued warnings about compounded semaglutide and tirzepatide products, citing risks including dosing errors, contamination, and lack of efficacy data. These are not equivalent to FDA-approved medications. Always obtain a prescription from and remain under the supervision of a board-certified physician.
Why an Endocrinologist vs. a General Practitioner?
Obesity frequently has underlying hormonal causes requiring specialist expertise to identify and treat. Dr. Puentes screens for:
- Hypothyroidism — an underactive thyroid directly lowers metabolic rate and promotes weight gain
- Insulin resistance or metabolic syndrome — often precedes and drives obesity
- Testosterone deficiency in men — causes fat accumulation and muscle loss
- Polycystic ovary syndrome (PCOS) in women — associated with insulin resistance and weight gain
- Hypercortisolism (Cushing’s syndrome) — rare but causes rapid, treatment-resistant weight gain
Identifying and treating these conditions alongside GLP-1 therapy produces significantly better outcomes than medication alone — and ensures safety.
Realistic Outcomes: What Clinical Evidence Shows
| Medication | Mean Weight Loss (Clinical Trials) | Study | Frequency |
| Semaglutide (Ozempic/Wegovy) | ~12–15% of body weight | STEP program, NEJM 2021 | Once weekly injection |
| Tirzepatide (Mounjaro/Zepbound) | ~15–22.5% of body weight | SURMOUNT-1, NEJM 2022 | Once weekly injection |
| Diet + exercise alone | ~3–5% of body weight | Multiple meta-analyses | Daily effort |
In clinical practice, Dr. Puentes reports that adherent patients may experience four to eight pounds of weight loss per month during the initial phase. Individual results vary and depend on baseline weight, commodities, lifestyle adherence, and metabolic response.
Frequently Asked Questions
Can I get these medications without a prescription or from an online pharmacy?
No. Semaglutide and tirzepatide are prescription medications. The FDA has issued warnings regarding compounded or unregulated versions sold online. Only an FDA -approved product obtained through a licensed physician and a regulated pharmacy is safe and legally compliant. Purchasing these medications without medical supervision poses serious health risks.
How long will I need to remain on GLP-1 therapy?
These are treatments for a chronic condition, not a short-term fix. Clinical studies show that when patients discontinue these medications, body weight tends to return to baseline over time. Dr. Puentes works with each patient to develop a long-term management strategy that may include dose reduction, lifestyle maintenance, or transition to other interventions as appropriate.
Are these medications safe for patients with type 2 diabetes?
Yes — for appropriate candidates. GLP-1 medications were originally developed for type 2 diabetes and have demonstrated both glycemic benefits and reduced cardiovascular risk in this population (LEADER trial for liraglutide, SUSTAIN-6 for semaglutide). Patients with diabetes should consult their endocrinologist to determine the optimal medication and dosage for their individual situation.
I have seen these medications advertised on social media. Is that safe?
Social media advertisements for weight loss medications — particularly those offering injections without physician oversight — should be approached with extreme caution. The FDA has specifically flagged unregulated compounded GLP-1 products as a patient safety concern. A comprehensive medical evaluation by a board-certified endocrinologist is the only appropriate starting point.
⚕️ MEDICAL DISCLAIMER: This article is written by Dr. Francisco Puentes, MD, FACE, a board-certified endocrinologist, for informational and educational purposes only. The content does not constitute medical advice, diagnosis, or treatment. Individual results vary. Always consult a qualified physician before beginning any medical treatment or making changes to your current healthcare plan. If you are experiencing a medical emergency, call 911 immediately.
For more information, please Contact Us
Dr. Francisco Puentes MD Endocrinology Specialists of Georgia
